I had a re-read of the previous posts of Southoz- grim reading! Very well put and makes it easy to understand some of the technicalities behind the trial result measurements.
Based on the P2 results and the measures they used It does make sense why no life science investment funds have invested and why it would appear they cant negotiate a ROW deal with a large upfront to give some immediate benefit to shareholders now. Given it was only a moderate increase is some measures it would be very hard to justify a large treatment price if a NDA is approved but again that is dictated by P3 results. I'm starting to think we have a white elephant on our hands.
Lanstead just about gone ., page-186
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |